Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organization (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the ...
According to MarketsandMarkets™, the Drug Discovery Technologies Market is projected to grow from about USD 30.58 billion in ...
Autonomy, by contrast, is about decision‑making and adaptation. The leap from automation to autonomy is not just more actuators; it is a system that can perceive its environment, reason about options, ...
Scientists often turn to high throughput screening (HTS) to quickly assay large-scale compound libraries against a desired target, accelerating life science research. New technologies and relevant ...
Metrion Biosciences ("Metrion"), the specialist preclinical contract research organization (CRO) and a global leader in ion channel services, today announced the launch of its validated, ...
New approach for anti-RSV compound discovery. The respiratory syncytial virus (RSV) has been identified as a major causative agent of bronchiolitis in children; nevertheless, avai ...
Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...
COPENHAGEN, Denmark, Feb. 17, 2021 /PRNewswire/ — Vipergen ApS announced today a published study describing a powerful new drug discovery approach that enables, for the first time, screening ...
CAMBRIDGE, England & KYIV, Ukraine--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback